It has been a bit of a writing hiatus as I have been in the middle of delivering a few...
This post/article is worth a read for those interested in the evolution of Pharma Business...
This follows last week’s post (Link) on the impact of M&A and licensing on FDA...
I recently read an interesting paper from Prof. Alexander Schuhmacher et al. on the impact...
1. Introduction In this project history, I’ll talk about an example of a proactive...
If you have decided to do a benchmarking exercise and collected a load of data, including...
It has been a bit of a writing hiatus as I have been in the middle of delivering a few short, intense...
This post/article is worth a read for those interested in the evolution of Pharma Business models: Pharma Exec – The Teva Turnaround...
This follows last week’s post (Link) on the impact of M&A and licensing on FDA drug approvals of leading pharmaceutical companies, based...
I recently read an interesting paper from Prof. Alexander Schuhmacher et al. on the impact of M&A and licensing on FDA drug...
It has been a bit of a writing hiatus as I have been in the middle of delivering a few short, intense...
This post/article is worth a read for those interested in the evolution of Pharma Business models:...
This follows last week’s post (Link) on the impact of M&A and licensing on FDA drug...
I recently read an interesting paper from Prof. Alexander Schuhmacher et al. on the impact of...
1. Introduction In this project history, I’ll talk about an example of a proactive company...
If you have decided to do a benchmarking exercise and collected a load of data, including primary...
This week’s recommendation is a book I’m in the process of reading through a second...
Ever find yourself mid-way through a research consulting project and disagreeing on what can be...
With the start of the new year, you may look at your company, business unit, or function and decide...